1. | tv52898 | |
2. | jesacoyote77 | |
3. | supper3638 | |
4. | dmchof94 | |
5. | ftbensoldier |
1. | tv52898 | |
2. | jesacoyote77 | |
3. | supper3638 | |
4. | dmchof94 | |
5. | ftbensoldier |
1. | jesacoyote77 04/17/2018 Basilea licenses late-stage oncology drug candidate derazantinib from ArQule |
2. | supper3638 06/13/2018 Oppenheimer initiates as an outperform, $7PT |
3. | jesacoyote77 04/17/2018 early? nah |
4. | tv52898 02/22/2018 seems accurate |
5. | dmchof94 02/22/2018 {Image} |
6. | dmchof94 04/17/2018 Looking to add some |
7. | supper3638 04/17/2018 Enters into license agreement with Basilea Pharmaceutica; Basilea will make an upfront payment to ArQule of … |
8. | supper3638 02/07/2018 ArQule and Roivant Sciences initiate a collaboration to pursue the development of derazantinib in Greater Ch… |
9. | jesacoyote77 02/04/2018 B. Riley FBR, Inc. raises to buy |
10. | jesacoyote77 02/22/2018 Wow, this is a double |